Joe Soto and Steven Hebert have been appointed to the roles of co-managing directors for FCBCure, FCB Health’s New Jersey office.
McCann Health has appointed Geline Midouin to global chief talent officer.
A lot can happen in 20 years. When the FDA Modernization Act (FDAMA) was passed in 1997, a mere 217 of its ~40,000 words were allocated to the presentation of healthcare economic information (HCEI). Those 217 words resided within Section 114 of the Act, giving birth to the abstract universe many of us now commonly refer to as FDAMA 114. Fast-forward to January 2017, and the FDA’s release of its Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities – Questions and Answers – Draft Guidance for Industry and Review Staff. Now 7,000+ words, this document is likely to significantly alter the way pharmaceutical manufacturers engage with the audience who increasingly holds the keys to its commercial success … payers such as health plans, pharmacy benefits managers (PBMs) and hospital systems.
The Coalition for Healthcare Communication (CHC) summit in Washington, D.C., in late November provided an interesting postmortem of the 2016 election, and a look into the crystal ball by some of our industry’s most knowledgeable leaders. Fast-forward to February 2017, and the crystal ball is still pretty cloudy.
The pharmaceutical ad agency natrel introduced a rebranding with the launch of a new website – natrelhealth.com – and redesigned social media pages.
The New York/New Jersey chapter of the Healthcare Businesswomen’s Association has opened up its mentoring program. Now in its ninth year, this comprehensive six-month program harnesses the power of accomplished professionals to help mentees set and achieve professional/career goals and forge new connections.
The fully integrated biopharma company Merrimack appointed a new president and CEO: Richard Peters, M.D., Ph.D.. He additionally became a member of Merrimack Pharmaceuticals’ board of directors.
Bayer appointed Dr. Carsten Brunn as president of its Pharmaceuticals business in the Americas, comprising the United States, Canada, Central America, and Latin America. In this role, Dr. Brunn reports to Dieter Weinand, member of the board of management of Bayer AG and president of the Pharmaceutical division.
Mathias Schmidt, Ph.D., has been named CEO of ArmaGen Inc. He also becomes a member of ArmaGen’s board of directors.
Eric Simmerman is now the first chief technology officer for HealthPrize Technologies.
